Objective: One mechanism underlying the link between multiple sclerosis (MS) and Epstein-Barr virus (EBV) might be a direct CNS infection. Viral CNS infections cause elevated antibody indices (AIs). Elevated EBV AIs were found in MS; however, patients with MS frequently show a polyspecific intrathecal immune response with elevated antiviral AIs. To discriminate whether elevated EBV AIs indicate a virus-driven or a polyspecific intrathecal immune response, we determined the intrathecal fraction of anti-EBV antibodies.
There is strong epidemiologic evidence linking multiple sclerosis (MS) to infection with the B-lymphotropic ␥-herpesvirus Epstein-Barr virus (EBV). 1, 2 However, the underlying mechanisms currently remain elusive. One hypothesis is that EBV or EBV-infected B cells might directly infiltrate the CNS, eliciting an EBV-specific immune response which subsequently leads to damage of surrounding tissue. 3, 4 CNS infections with herpesviruses typically result in the production of antiviral antibodies within the CNS, 5, 6 which can be detected by an elevated antibody index (AI). 7, 8 Notably, also about 90% of patients with MS show elevated AIs against one or more neurotropic viruses, in particular, measles virus, rubella virus, and varicella zoster virus (VZV). 9 In patients with MS, these elevated virus-specific AIs are not thought to be due to a virus-driven immune response, but rather to a polyspecific activation of intrathecal B cells, whose origin is albeit poorly understood. Previous studies reported the detection of elevated EBV AIs in varying proportions of patients with MS. [10] [11] [12] [13] [14] [15] Nevertheless, even strongly elevated antiviral AIs do not discriminate between a focused virus-driven immune response, as observed in genuine viral CNS infections, or a polyspecific immune response, as seen in patients with MS. 6 The only methodologic approach that currently allows us to discriminate between a microorganism-driven and a polyspecific humoral intrathecal immune response is to determine the specific intrathecal fraction (F S ) of an antiviral antibody. 6, 16, 17 Here, we determined F S for anti-EBV antibodies in patients with a clinically isolated demyelinating syndrome (CIS) or MS and an intrathecal synthesis of anti-EBV antibodies.
METHODS Patients. Two cohorts of patients were included in this study. Cohort 1 consisted of 24 patients (16 women, 8 men) with a CIS (n ϭ 7) or MS (n ϭ 17) according to the revised Mc-Donald criteria. 18 The median (range) age of patients of cohort 1 was 38 (21-60) years. All patients included in cohort 1 had an elevated EBV AI (Ն2.0), as identified by review of the laboratory files of the Institute of Virology, Charité-University Medicine, Berlin, Germany, where EBV AI determinations had been performed for diagnostic purposes. To reduce the risk of inclusion of falsepositive patients we purposefully chose a cutoff of an EBV AI Ն2.0 rather than the normally used cutoff of Ն1.5 as an inclusion criterion. Thirteen patients with MS had relapsing-remitting MS, 2 secondary progressive MS, and 2 primary progressive MS. Cohort 2 comprised 36 patients (26 women, 10 men) with a CIS manifesting as optic neuritis in whom EBV AIs had not previously been determined. The median (range) age of patients of cohort 2 was 33 (16 -58) years. All patients with CIS in cohort 1 and all patients in cohort 2 had at least 1 (range 1-30) T2 hyperintense lesion on MRI in a location considered characteristic for MS, i.e., juxtacortical, periventricular, infratentorial, or spinal cord. 19 Three female patients (19, 57 , and 70 years old) who had undergone kidney or lung or liver transplantation and subsequently developed a cerebral manifestation of post-transplantation lymphoproliferative disorder (PTLD) were studied as well.
Serum and CSF samples, collected between March 2004 and April 2009, and stored at Ϫ20°C, were available for all patients. To exclude a confounding influence of artificial blood contamination on AI determinations, only CSF samples with an erythrocyte count of Ͻ400/L were analyzed. 20 The median (range) CSF white cell count per L, as manually determined with a Fuchs-Rosenthal counting chamber, of patients of cohort 1, cohort 2, and patients with PTLD was 10 (2-73), 8 (1-42), and 15 (8 -19) , respectively. All patients included in this study had an intrathecal immunoglobulin G (IgG) synthesis as evidenced by the detection of oligoclonal bands in CSF not present in serum. 5
Standard protocol approvals and patient consents.
Lumbar punctures were performed with written informed consent from all patients or their guardians. The usage of stored serum and CSF samples for the purposes of this study was approved by the institutional review board, Charité University Medicine, Berlin, Germany (EA1/126/10).
Measurement and calculation of virus-specific antibody indices.
Antibodies against EBV, measles virus, VZV, and herpes simplex virus (HSV) were determined in serum and CSF samples using commercial ELISA (Enzygnost, Siemens Healthcare Diagnostics, Eschborn, Germany) according to the manufacturer's instructions. Antibodies against rubella virus were measured by ELISA (Medac, Wedel, Germany) as well. According to data provided by the manufacturers, the mean intra-assay and interassay coefficients of variation of the different ELISA kits were as follows: EBV (6.5%, 6.7%), measles virus (7.2%, 14%), VZV (3.6%, 13.1%), HSV (8.3%, 7.8%), rubella virus (5%, 10%). The Enzygnost Anti-EBV ELISA plate is coated with antigens from EBV-infected lymphoblastoid cell lines comprising viral capsid antigen, Epstein-Barr nuclear antigens, and early antigen. A standard curve consisting of serial dilutions of standard human plasma (SHP, Siemens Healthcare Diagnostics) was included on each ELISA plate. The same batch of SHP was used for all experiments. Total albumin and IgG concentrations in serum and CSF were measured nephelometrically (BN ProSpec, Siemens Healthcare Diagnostics).
AI values were calculated with the formula AI ϭ (IgG spec CSF/ IgG spec serum)/(IgG total CSF/IgG total serum) ϭ (quotient CSF/ serum specific IgG)/(quotient CSF/serum total IgG) ϭ Q spec /Q IgG if Q IgG Ͻ Q Lim , or AI ϭ Q spec /Q Lim if Q IgG Ͼ Q Lim . 7 Q Lim was calculated as described. 5 AI values Ն1.5 were considered as indicative of an intrathecal virus-specific antibody production. 7
Determination of the intrathecal fraction Fs. F S is the fraction (in %) of the intrathecally synthesized virus-specific IgG concentration of the total intrathecally synthesized IgG concentration. Calculation of F S for EBV antibodies requires determination of the absolute concentration (in g/mL) of EBV-specific IgG antibodies in serum and CSF. Experimental samples must therefore be tested in parallel with a standard curve, for which we used SHP, with a known concentration of EBV-specific IgG. The concentration of EBV-specific IgG in SHP was determined as described before 6 by constructing an ELISA with one strip from a commercial human IgG ELISA (AJ Roboscreen, Leipzig, Germany) and one strip from the Enzygnost EBV ELISA. The IgG strip was incubated with serial dilutions (12.5 to 1.56 ng/ mL) of a defined human IgG standard and the EBV strip with serial dilutions of SHP. Strips were developed with reagents included in the human IgG ELISA kit, using horseradish peroxidase conjugated antihuman IgG at a dilution of 1:15. The concentration of EBV-specific IgG in SHP was then calculated under the definition that 1 g EBV-specific IgG has the same optical density (OD) as 1 g total IgG. Four dilutions (1:704, 1:1,408, 1:2,816, 1:5,632) of SHP had ODs within the linear range of the IgG standard curve and the calculated EBV-specific IgG concentrations for these dilutions were 8.7, 10.4, 10.9, and 11.3 g/mL. We took the mean of these values (10.3 g/mL) as the concentration of EBV-specific IgG in SHP. The concentration of measles antibodies in SHP was determined by analogy. Again, 4 SHP dilutions (1:2,640, 1:5,280, 1:10,560, 1:21,120) had ODs within the linear range of the IgG standard curve, resulting in measles-specific IgG concentrations of 29.5, 29.5, 30, and 28 g/mL. The mean of those values (29.3 g/mL) was taken as the concentration of measles-specific IgG in SHP.
F S values were determined as ratio of the intrathecally produced concentration of virus-specific antibodies (AB Loc ) and the concentration of intrathecally synthesized total IgG (IgG Loc ). As previously described in detail, 6 for comparison of means in different groups F S refers to Q mean instead of Q Lim . Therefore, F S was calculated by the formula F S ϭ AB Loc (mean)/IgG Loc 6 Notably, F S can only be calculated for Q IgG Ͼ Q mean and in cases of a proven intrathecal virus-specific antibody synthesis, as defined by an AI Ն1.5. 6 Statistical significance of differences of F S values was assessed by 2-tailed Mann-Whitney U test using GraphPad Prism 5.03.
RESULTS
Intrathecally produced antibodies against EBV are part of the polyspecific intrathecal immune response in patients with CIS and MS. We first identified 24 patients with a CIS or MS (cohort 1) with an EBV AI Ն2.0, as previously determined during the patient's diagnostic workup. EBV AIs for all patients of cohort 1 were then redetermined, including a standard curve with a defined anti-EBV antibody concentration on each ELISA plate. EBV AIs obtained in the 2 runs correlated well (R 2 ϭ 0.92), demonstrating a good reproducibility of the method and preservation of antibodies in stored serum and CSF samples (data not shown). Importantly, in all retested samples EBV AIs remained elevated (Ն1.5), allowing for calculation of F S for anti-EBV antibodies (F S anti-EBV). As positive controls, we also studied 3 patients with a cerebral manifestation of PTLD, a lymphoproliferative neoplastic disease occurring after solid organ transplantation, in which EBV is thought to play a causative role. 21 EBV DNA was detectable by quantitative PCR in CSF of all 3 patients with PTLD with 4,920, 8,720, and 17,000 copies per mL, demonstrating the presence of EBV in the CNS in all of those 3 patients. The median F S anti-EBV of patients in cohort 1 was 0.65% (table), meaning that only 0.65% (median) of all intrathecally produced antibodies were directed against EBV. Except for one patient with a CIS and an unusually high F S anti-EBV (18.21%), F S anti-EBV ranged between 0.01% and 4.78%, that is, F S anti-EBV was generally less than 5% (figure 1). In contrast, in patients with a cerebral PTLD, median F S anti-EBV was 27.82%. The median amount of intrathecally produced anti-EBV antibodies was thus about 40-fold higher in patients with PTLD compared to patients with MS (p ϭ 0.008, Mann-Whitney U test). Excluding the patient with CIS with an unusually high F S anti-EBV, there was no overlap of F S anti-EBV values between patients with CIS/MS and PTLD (figure 1). Conversely, EBV AI values completely overlapped between the 2 groups (1.5 to 22.1 for CIS/MS; 4 to 13.3 for PTLD), confirming that AIs do not discriminate between virus-driven and polyspecific intrathecal immune responses (table) .
To directly compare F S anti-EBV with the F S for another antiviral antibody, we also determined F S for anti-measles antibodies in a subgroup of patients from cohort 1 who had measles AIs Ն1.5 (see also next paragraph, table, and figure 2). F S values for measles antibodies (median 0.9%) and EBV antibodies were not different ( p ϭ 0.23, Mann-Whitney U test). None of the patients with PTLD showed an elevated measles AI, indicating that the intrathecal immune response in these patients is focused against EBV (table). We conclude that, just like intrathecally produced measles antibodies, intrathecally produced EBV antibodies are part of the polyspecific intrathecal immune response in patients with CIS/MS.
Intrathecal synthesis of EBV antibodies is associated with intrathecal synthesis of antibodies against other neurotropic viruses in patients with CIS/MS. To analyze how intrathecal production of EBV antibodies
relates to the production of antibodies against other neurotropic viruses in patients with CIS/MS, we also determined AIs for measles virus, rubella virus, VZV, and HSV in the 24 patients with an elevated EBV AI (figure 2). All 24 patients with a CIS or MS and an elevated EBV AI had at least one further virusspecific AI Ն1.5 and many patients had multiple elevated virus-specific AIs. In detail, 10, 5, 3, and 6 of the patients with an EBV AI Ն1.5 showed 1, 2, 3, or 4 further AIs Ն1.5.
Intrathecal production of antibodies against EBV is rare in early MS. While the data obtained so far did not support the hypothesis of a virus-driven intrathecal anti-EBV antibody synthesis in MS, it is conceivable that such a phenomenon might specifically occur during the early phase of the disease but becomes undetectable in the later course. 2, 10, 22 We therefore determined the frequency of an EBV AI Ն1.5 in a cohort of 36 patients with a CIS manifesting as optic neuritis. A total of 26 of 36 (72.2%) serum/CSF pairs were collected within 1 month after onset of clinical symptoms and for the remaining patients the maximum interval to sample collection was 5 months, indicating that the investigated samples were representative of the early phase after clinical manifestation of the disease. Anti-EBV antibodies were detected in serum of all (100%) patients with optic neuritis. However, only 2 of 36 (5.6%) patients had an EBV AI Ն1.5 (1.5 and 1.9); the corresponding F S anti-EBV values in these 2 patients were 0.12% and 0.41%.
DISCUSSION
To clarify whether elevated EBV AIs in patients with CIS/MS indicate a virus-driven or a polyspecific intrathecal immune response, we determined the intrathecally produced fraction of EBVspecific IgG of the total intrathecally produced IgG (F S anti-EBV) in a cohort of 24 patients with CIS/MS and elevated EBV AIs. Indeed, it was previously shown that in virus-driven humoral intrathecal immune responses, for instance, in patients with HSV encephalitis or subacute sclerosing panencephalitis (SSPE), median F S values for HSV and measles virus antibodies are as high as 9% and 19%, whereas in the polyspecific immune response in patients with MS, median F S values for antibodies against HSV and measles virus are substantially lower (0.1% and 0.5%). 6 In the present work, we found that F S anti-EBV was overall less than 5% and did not differ from the intrathecally produced fraction of measles antibodies. The F S anti-EBV values obtained herein are in the same range as the previously reported F S values of less than 5% for measles virus, rubella virus, VZV, and HSV in patients with MS. 6 Our data therefore strongly suggest that intrathecally produced anti-EBV antibodies are part of the polyspecific intrathecal humoral immune response in patients with CIS/MS and do not result from a virusdriven EBV-specific intrathecal humoral immune response. This is further supported by the frequent concomitant detection of intrathecally produced antibodies against measles virus, rubella virus, VZV, and HSV in patients with CIS/MS with an intrathecal synthesis of EBV antibodies. Altogether, our findings argue against the hypothesis of a direct CNS infection with EBV, as evidenced by an intrathecal virus-driven antibody synthesis, in patients with CIS/MS. This is in accordance with several recent studies that, in contrast to an initial report, 3 detected The fraction of EBV-(F S anti-EBV) and measles-specific (F S anti-measles) intrathecally synthesized immunoglobulin G (IgG) of the total intrathecally synthesized IgG was determined in patients with clinically isolated syndrome (CIS)/MS (n ϭ 24) or cerebral PTLD (n ϭ 3), as described in Methods. F S anti-measles was calculated for n ϭ 12 patients with a measles antibody index Ն1.5. Horizontal bars represent median F S values. The dashed line indicates an F S of 5%. Significance of differences between groups was assessed by Mann-Whitney U test.
Figure 2 Intrathecal production of antiviral antibodies in patients with multiple sclerosis (MS) and an elevated Epstein-Barr virus (EBV) antibody index (AI)
AIs for antibodies against the indicated viruses were determined in 24 patients with a clinically isolated syndrome (CIS) or MS who had an EBV AI Ն1.5. Horizontal bars represent median AI values. Patients who were seronegative for antibodies against the respective viruses (measles virus, n ϭ 5; rubella virus, n ϭ 3; herpes simplex virus [HSV], n ϭ 10; varicella zoster virus [VZV], n ϭ 2) were excluded. The dashed line indicates the cutoff of Ն1.5 above which AIs are considered elevated.
EBV nucleic acids or proteins in MS brain tissue samples only rarely or not at all. 13, 22, 23 One out of 24 patients with CIS/MS and an EBV AI Ն1.5 showed an unusually high F S anti-EBV (18.21%). This patient was a 35-year-old woman with a CIS presenting as optic neuritis. Clinical and paraclinical findings of this patient were similar to those of the other patients of the cohort. In addition to a strongly elevated EBV AI (22.1) she also had an elevated rubella virus AI (1.7). To analyze the possibility that the high F S anti-EBV of this patient was due to presence of EBV in the CNS we searched for EBV DNA by quantitative PCR in her CSF, which was negative. Altogether, we believe that the F S anti-EBV value of this patient represents an outlier that does not change the interpretation of our findings.
Median F S anti-EBV was about 40-fold higher in patients with a cerebral PTLD than in patients with CIS/MS, reminiscent of the previously reported approximately 40-fold higher F S anti-measles values in patients with SSPE as compared to patients with MS. 6 This indicates that, similar to the measles virusdriven intrathecal humoral immune response in patients with SSPE, there is a strong EBV-driven intrathecal humoral immune response in patients with cerebral PTLD, which, to our knowledge, has not been recognized until now. Further studies on the diagnostic value of F S anti-EBV determinations in cerebral PTLD involving larger numbers of patients appear warranted. Since cerebral PTLD may be considered a virus-driven neoplastic disease rather than a genuine CNS infection it would certainly also be interesting to study F S anti-EBV in patients with EBV-associated meningitis or encephalitis. Nevertheless, so far we were unable to identify patients with EBV meningitis or encephalitis as proven by presence of EBV DNA in the CSF that at the same time show an elevated EBV AI and Q IgG Ͼ Q mean , which both are prerequisites for determination of F S anti-EBV.
The low frequency of elevated EBV AIs in patients with a CIS manifesting as optic neuritis does not support the concept that an intrathecal humoral immune response against EBV might be particularly prominent in the early phase of the disease and declines thereafter. Since all patients with optic neuritis included in this study had characteristic features (intrathecal IgG synthesis, Ն1 T2 hyperintense lesions on MRI) of optic neuritis occurring in the setting of a CIS heralding MS, it seems unlikely that our results might be due to inclusion of atypical cases. The low prevalence of an elevated EBV AI in patients with a CIS (5.6%) is similar to the previously reported low prevalence (10%) of an EBV AI Ն1.5 in patients with MS. 11 Remarkably, we observed a 100% sero-positivity rate for EBV in the group of patients with CIS, suggesting that the well-established near 100% EBV seroprevalence in patients with MS 1 may also extend to patients with CIS. The 100% EBV seroprevalence in patients with the earliest clinical manifestation of MS is compatible with the concept that infection with EBV precedes the clinical onset of MS. 24 Altogether, we show that in patients with CIS/MS with an intrathecal synthesis of anti-EBV antibodies this phenomenon is part of the polyspecific intrathecal humoral immune response typically seen in patients with CIS/MS. Furthermore, intrathecal production of anti-EBV antibodies is rare in patients with a CIS. Our data argue against the hypothesis that a CNS infection with EBV, as evidenced by a virus-specific intrathecal antibody response, may explain the association of EBV infection and MS. The mechanisms underlying the association of EBV and MS remain to be elucidated. Different and possibly novel hypotheses will have to be generated and tested.
